Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Supernus Pharmaceuticals, Inc. SUPN
$33.39
-$2.33 (-6.99%)
На 18:00, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
1963874220.00000000
-
week52high
42.09
-
week52low
25.08
-
Revenue
667238000
-
P/E TTM
33
-
Beta
1.04775000
-
EPS
1.04000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Jefferies | Buy | Hold | 13 апр 2021 г. |
| Piper Sandler | Overweight | Neutral | 16 июн 2020 г. |
| Jefferies | Hold | Hold | 15 июн 2020 г. |
| Stifel | Hold | Hold | 16 апр 2020 г. |
| Stifel Nicolaus | Hold | Buy | 07 ноя 2019 г. |
| Piper Sandler | Overweight | Overweight | 31 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Khattar Jack A. | D | 47882 | 498 | 01 февр 2023 г. |
| Khattar Jack A. | D | 795159 | 300 | 01 февр 2023 г. |
| Khattar Jack A. | A | 795459 | 498 | 01 февр 2023 г. |
| Khattar Jack A. | D | 48380 | 1620 | 31 янв 2023 г. |
| Khattar Jack A. | D | 794961 | 976 | 31 янв 2023 г. |
| Khattar Jack A. | A | 795937 | 1620 | 31 янв 2023 г. |
| Khattar Jack A. | D | 50000 | 8080 | 18 янв 2023 г. |
| Khattar Jack A. | D | 794317 | 4936 | 18 янв 2023 г. |
| Khattar Jack A. | A | 799253 | 8080 | 18 янв 2023 г. |
| Khattar Jack A. | D | 58080 | 41920 | 17 янв 2023 г. |
Новостная лента
Supernus (SUPN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks Investment Research
09 мая 2023 г. в 22:09
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2023 Earnings Call Transcript
Seeking Alpha
09 мая 2023 г. в 21:43
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, IR Jack Khattar - CEO Tim Dec - CFO Conference Call Participants Andrew Tsai - Jefferies David Amsellem - Piper Sandler Jack Padovano - Stifel Operator Good afternoon, and welcome to Supernus Pharmaceuticals First Quarter 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode.
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Beat Estimates
Zacks Investment Research
09 мая 2023 г. в 20:37
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.43 per share a year ago.
Supernus to Present at the Bank of America 2023 Health Care Conference
GlobeNewsWire
02 мая 2023 г. в 16:05
ROCKVILLE, Md., May 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat, as well as host investor meetings, at the Bank of America 2023 Health Care Conference on Thursday, May 11, 2023, at 10:40 a.m. PT (1:40 p.m. ET).
Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023
GlobeNewsWire
25 апр 2023 г. в 16:15
ROCKVILLE, Md., April 25, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2023 after the market closes on Tuesday, May 9, 2023.